ISHL13 Videos

Introduction

Molecular and microenvironmental vulnerabilities of B-cell lymphomas

Sirpa Leppä

Is there a role for CAR T-cell therapy in first-line Tx of indolent lymphoma?

Marie Jose Kersten

Who needs bispecific antibodies as first-line treatment in aggressive lymphoma?

Catherine Thieblemont

How to implement novel ADCs in the first-line treatment of lymphoma

Pier Luigi Zinzani

Perspectives of small molecule based first-line therapy of LBCL

Theodoros Vasilakopoulos

Treatment and Trial Landscape for Malignant Lymphoma in China

Yuqin Song

IIntro: Treatment concepts in early-stage HL

Marc André

Viewpoint: Systemic Therapy only in the future?

Ranjana Advani

Viewpoint: CMT (is it there to stay?)

Joachim Yahalom

Factors driving treatment intensity in the whole cohort of patients with early-stage favorable (I-IIA), nonbulky Hodgkin Lymphoma enrolled in the RAFTING trial (NCT 04866654).

Andrea Gallamini

Nodular lymphocyte predominant Hodgkin lymphoma in the Nordic countries – characteristics, treatment and survival

Ingrid Glimelius

Serum TARC Dynamics Correlate with Clinical Response and Metabolic Tumor Volume During Anti-PD1-Based First-Line HL Treatment in The GHSG Phase II NIVAHL Trial

Wouter Plattel

Welcome and Introduction

Christian Buske

BTKis in indolent lymphomas (FL, MZL)

Catherine Thieblemont

BTKis in WM

Christian Buske

BTKis in MCL

David Lewis

Future developments (CDAC, BCL2, anti PD1/PDL1)

Anna Maria Frustaci

Panel discussion, audience Q&A

Closure and farewell

Christian Buske

Recent achievements and future goals in Pediatric and Young Adult HL: COG Perspective

Sharon Castellino

Recent achievements and future goals in Pediatric and Young Adult HL: EuroNET-PHL Perspective

Christine Mauz-Körholz

Appropriate endpoints for future trials in Pediatric and Young Adult HL, and opportunities for harmonization

Jamie Flerlage, Kara Kelly

Pathogenesis of HL

Ralf Küppers

EFFICACY and TOLERABILITY in DECOPDAC21 versus COPDAC28 in PEDIATRIC INTERMEDIATE and ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: INTERIM RESULTS of the EURONET-PHL-C2 RANDOMIZED STUDY

Dieter Körholz

Multimodal characterization of cHL

Christian Steidl

Progression-Free Survival (PFS) with Nivolumab-AVD is superior to Brentuximab Vedotin-AVD with 2-year follow-up of S1826 in Adolescent Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL)

Sharon Castellino

Updated Results from the Phase 2 KEYNOTE-667 Study: Pembrolizumab (pembro) in Children and Young Adults With Low-Risk Classical Hodgkin Lymphoma (cHL) and Slow Early Response (SER) to Front-Line Chemotherapy (chemo)

Kara Kelly

Characterization of cancer-associated fibroblasts and their spatial architecture reveals heterogeneity and survival associations in classical Hodgkin lymphoma

Kristiina Karihtala

Circulating tumor DNA sequencing facilitates biological classification and individualized risk stratification in patients with Hodgkin lymphoma

Michel Heger

Distinct cell state ecosystems for nodular lymphocyte-predominant Hodgkin lymphoma

Michael Binkley

Multi-Dimensional Profiling Unveils Distinct Molecular Subtypes in Classic Hodgkin Lymphoma

Tomohiro Aoki

B-cell lymphoma pathology – illustrated for non- pathologists

Wolfram Klapper

Classical Hodgkin Lymphoma - Development of immune checkpoint inhibition beyond PD-1 blockade

Peter Borchmann

Diffuse Large B-cell Lymphoma - The current and future role of ADC in the context of immunotherapies

Sascha Dietrich

Implementing Frailty Assessment for Treatment Guidance in HL

Sarah Rutherford

Optimal Use of Targeted Agents to Address Unmet Need in Older HL

Graham Collins

A simplified frailty score predicts outcome in older patients with classical Hodgkin lymphoma treated with curative intent

Kjersti Lia

Characterisation of older Hodgkin Lymphoma patients using UK registry data from 1997-2023

Aisling Barrett

Feasibility and Efficacy of PET-guided BrECADD in Older Patients with Advanced-Stage classical Hodgkin Lymphoma: The Older Cohort of the International GHSG HD21 Trial

Justin Ferdinandus

Nivolumab-AVD improves 2-year progression-free and overall survival compared to Bv-AVD in older patients aged ≥60 years with advanced stage classical Hodgkin lymphoma (cHL) enrolled on SWOG S1826

Sarah Rutherford

Spotlight on ECHELON-1: 7-year survival data

John Radford

Real-world insights: frontline treatment of stages III & IV cHL

Chiara Rusconi

Q&A

cHL in the real-world: a case study approach

Carolina Valeria Mahuad, John Radford

Individualized treatment de-escalation improves overall outcomes

Peter Borchmann

Immune-chemotherapy overcomes the need for individualization

Jonathan Friedberg

2-Year Follow-up of the S1826 Study Confirms Improved Progression-Free Survival with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Advanced Stage Classic Hodgkin Lymphoma

Alex Herrera

Development and application of a validated MRD assay in Hodgkin Lymphoma

Julia Mattlener

EORTC-1537-COBRA: PHASE II STUDY OF VERY EARLY FDG-PET-RESPONSE ADAPTED TARGETED THERAPY FOR ADVANCED HODGKIN LYMPHOMA. PRIMARY ANALYSIS INCLUDING VALUE OF QUANTITATIVE PET ASSESSMENT AND TARC DYNAMICS

Martin Hutchings

Metabolic tumor volume after two cycles of chemotherapy in patients treated for advanced-stage Hodgkin Lymphoma: analysis of the German Hodgkin Study Group phase III HD18 and HD21 trials

Justin Ferdinandus

NLPHL: HL, NHL or something else?

Sylvia Hartmann

First-line treatment of NLPHL with HL-directed approaches

Dennis Eichenauer

Treatment of NLPHL with NHL-directed approaches

Graham Collins

Q&A

Sylvia Hartmann, Dennis Eichenauer, Graham Collins

Late consequences of drugs used in the modern era of treatment for HL (to include anthracyclines, bleomycin, checkpoint inhibitors, ADCs)

Stephen Ansell

Starting Living beyond Lymphoma with HL diagnosis

Karolin Behringer, Maximilian Büttner

Participation in and (cost-)effectiveness of the Dutch HL survivorship care program

Annelies Nijdam, Berthe Aleman

A priori estimation of mediastinal toxicities after radiotherapy for Hodgkin Lymphoma - A secondary analysis of the HD16/17 Trial by the German Hodgkin Study Group using normal tissue complication probability calculations

Michael Oertel

Concordance between late effects reported by physicians and patients in a cohort of long-term Hodgkin lymphoma survivors: an analysis of data from nine consecutive EORTC-LYSA trials

Sidsel Juul

Novel 3D speckel tracking imaging modality in detecting cardiac toxicity in asymptomatic pediatric HL survivors

Zeinab Salah Seliem

Updated approach to second-line treatment

Alison Moskowitz

Emerging strategies to overcome anti-PD1 resistance

Stephen Ansell

Implementing raditoherapeutic concepts in rrHL care

Christian Baues

Longitudinal circulating tumor DNA sequencing may predict the response to PD1 blockade therapy in relapsed/refractory classical Hodgkin Lymphoma patients

Francesco Corrado

Pembrolizumab maintenance instead of autologous hematopoietic cell transplantation for patients with relapsed or refractory Hodgkin lymphoma in complete response after pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin

Alison Moskowitz

Brentuximab Vedotin - ESHAP Significantly Increases the Metabolic Complete Remission Rate versus ESHAP in Relapsed Classical Hodgkin’s Lymphoma. Final Results of the BRESELIBET Prospective Trial.

Anna Sureda

Workshop Report

Sally Barrington, Sven Borchmann, Carsten Kobe, Wouter Plattel, Davide Rossi

Best of ISHL13

Ranjana Advani

Farewell

Peter Borchmann

Keynote Lecture

Linda Partridge

Welcome Address

Peter Borchmann, Volker Diehl

Award Ceremony

Sven Borchmann, Paul J. Bröckelmann, Peter Borchmann, Dennis Eichenauer